In compound heterozygous subjects for F508del- and G551D-CFTR, the effects observed in SCC and ppFEV1 were greater with the addition of TEZA than the effects observed for IVA monotherapy, indicating the potential of the combined therapy for this CF population [27]. The gene discussed is CFTR; the disease is cystic fibrosis.